Stocks
TG Therapeutics, Inc.TGTX
NASDAQHealthcareBiotechnology$27.96+3.79%
Focused on developing novel treatments for B-cell malignancies and autoimmune diseases, this biopharma has gained investor attention for its FDA-approved therapies targeting blood cancers. The company's lead drug, Ukoniq, was voluntarily withdrawn in 2022 due to safety concerns, but its multiple sclerosis treatment Briumvi shows commercial potential.
Market Cap: $4.5B52W Range: $25.28 – $46.48
Congressional Interest in TG Therapeutics, Inc. (TGTX)
1 member of Congress has disclosed 1 trade in TG Therapeutics, Inc. (TGTX), a Healthcare company. The buy/sell breakdown shows 0 purchases versus 1 sale, indicating net selling pressure from lawmakers. All data is sourced from STOCK Act periodic transaction reports filed with Congress.
Total Disclosures
1
Unique Politicians
1
Buys
0
Sells
1
Who in Congress Is Trading TGTX?
| Date | Politician | Type | Amount |
|---|---|---|---|
| 2020-09-08 | Christopher L. Jacobs | sell | $1K – $15K |